關(guān)鍵詞

?抗體 流感 肺炎 B細(xì)胞 基因 阿爾茨海默病

?

#今日行業(yè)熱點#

①MABS ：Blueprint for antibody biologics developability

綜述：抗體生物制劑可開發(fā)性的藍(lán)圖

DOI :10.1080/19420862.2023.2185924

②Journal of Medical Virology：The Clinical Predictors of and Vaccine Protection Against Severe Influenza Infection in Children

兒童抗嚴(yán)重流感感染的臨床預(yù)測因素和疫苗保護(hù)作用

DOI :10.1002/jmv.28638

③Journal of Experimental Medicine：Humans with inherited MyD88 and IRAK-4 deficiencies are predisposed to hypoxemic COVID-19 pneumonia

遺傳性MyD88或IRAK-4缺乏有發(fā)生低氧性COVID-19肺炎的高風(fēng)險

DOI :10.1084/jem.20220170

④Journal of Experimental Medicine：B cell receptor ligation induces IgE plasma cell elimination

B細(xì)胞受體連接誘導(dǎo)IgE漿細(xì)胞清除

DOI :10.1084/jem.20220964

⑤GeroScience：Proteomic basis of mortality resilience mediated by FOXO3 longevity genotype

FOXO3彈性基因型通過降低相關(guān)通路的死亡率來發(fā)揮作用

DOI :10.1007/s11357-023-00740-6

⑥Gut：Gnotobiotic mice housing conditions critically influence the phenotype associated with transfer of faecal microbiota in a context of obesity

肥胖條件下，居住條件嚴(yán)重影響與糞便微生物群轉(zhuǎn)移相關(guān)的表型
DOI :10.1136/gutjnl-2021-326475

⑦德喜曲妥珠單抗（Trastuzumab Deruxtecan）Ⅱ期臨床試驗數(shù)據(jù)公布，在表達(dá)HER2晚期實體瘤中達(dá)到ORR終點

⑧用于早期阿爾茨海默病的Lecanemab基于IIb期概念驗證性臨床試驗數(shù)據(jù)獲FDA批準(zhǔn)sBLA優(yōu)先審評資格

⑨中國生物：采用新型抗原設(shè)計的新型冠狀病毒mRNA疫苗I期臨床試驗啟動

⑩FDA已接受度普利尤單抗（Dupixent）用于成人和青少年慢性自發(fā)性蕁麻疹補(bǔ)充生物制品許可申請(sBLA)審查

科學(xué)探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴的合作伙伴！